Roivant Sciences Ltd. Ratios | P/E, ROE & Valuation

On the Key Ratios page for Roivant Sciences Ltd. (ROIV), the latest P/E of -91.2 frames valuation, while ROE -6.12% and ROIC -27.14% indicates profitability and capital efficiency. Together with the current ratio of 16.72 and debt-to-equity 0.03, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

ROIV Historical Per Share Metrics

7 years
Metric (FY)TTM202420232022202120202019
Revenue per Share$0.01$0.04$0.04$0.09$0.08$0.03$0.10
Net Income per Share$-0.37$-0.24$5.55$-1.42$-1.26$-1.18$1.75
Operating Cash Flow per Share$-1.12$-1.16$-0.98$-1.18$-1.01$-0.81$-1.11
Free Cash Flow per Share$-1.13$-1.16$-0.98$-1.20$-1.04$-0.81$-1.12
Cash per Share$5.33$6.74$8.35$2.36$3.08$3.11$3.19
Book Value per Share$6.83$7.15$8.23$2.26$3.08$3.16$3.08
Tangible Book Value per Share$6.83$7.15$8.06$2.05$3.08$3.16$3.08
Interest Debt per Share$0.15$0.14$0.68$0.71$0.43$0.36$0.28
CAPEX per Share$0.01$0.01$0.00$0.02$0.03$0.01$0.01

ROIV Historical Valuation Ratios

7 years
Metric (FY)TTM202420232022202120202019
Price to Earnings (P/E)-91.16-42.561.88-5.21-3.91-8.285.93
Price to Book (P/B)5.91.561.374.5423.733.5
Price to Sales (P/S)3322.38251.93249.7385.8459.84281.46105.21
Enterprise Value to EBITDA-84.89-4.28-2.66-3.45-1.68-6.78-9.25
EV to Sales3170.85161.9165.2166.3327.71205.3975.6
EV to Operating Cash Flow-29.51-5.6-2.79-4.82-2.26-8.85-6.72
EV to Free Cash Flow-29.34-5.57-2.78-4.75-2.2-8.76-6.67
Enterprise Value$23.88B$4.70B$2.13B$4.06B$1.53B$4.89B$5.12B

ROIV Historical Profitability Ratios

7 years
Metric (FY)TTM202420232022202120202019
Return on Equity (ROE)-6.12%-3.67%72.86%-87.15%-51.01%-45.01%59.08%
Return on Invested Capital (ROIC)-27.14%-20.28%64.15%-54.40%-56.06%-45.02%-22.53%
Return on Tangible Assets-5.02%-3.16%61.39%-44.95%-32.70%-30.09%48.47%
Earnings Yield-1.07%-2.35%53.24%-19.18%-25.55%-12.08%16.86%
Free Cash Flow Yield-3.25%-11.53%-9.38%-16.27%-21.01%-8.33%-10.77%
Dividend Yield0.00%0.00%0.07%0.00%0.00%0.00%0.00%

ROIV Historical Liquidity & Financial Strength

7 years
Metric (FY)TTM202420232022202120202019
Current Ratio16.7233.4725.246.611.649.9924.09
Interest Coverage00129.31-42.02-191.97-381.24-69.3
Income Quality2.242.35-0.180.760.730.611.47
Debt to Equity0.030.020.080.420.170.140.09
Debt to Assets2.02%1.84%6.92%20.15%10.98%9.11%7.30%
Net Debt to EBITDA4.062.387.521.011.952.513.62

ROIV Historical Efficiency Ratios

7 years
Metric (FY)TTM202420232022202120202019
Receivables Turnover0.0100.41.638.211.724.43
Payables Turnover0.060.040.030.350.260.10.11
Inventory Turnover000.054.75000
Days Sales Outstanding38439.70924224.2244.44212.1782.39
Days Payables Outstanding6470.43949212149.551051.791407.853646.453325.99
Days of Inventory on Hand008046.6676.76000

ROIV Historical Market Metrics

7 years
Metric (FY)TTM202420232022202120202019
Enterprise Value to EBITDA-84.89-4.28-2.66-3.45-1.68-6.78-9.25
Market Cap$25.02B$7.32B$8.17B$5.26B$3.31B$6.70B$7.12B
Enterprise Value$23.88B$4.70B$2.13B$4.06B$1.53B$4.89B$5.12B
Dividend Yield0.00%0.00%0.07%0.00%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.14%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does Roivant Sciences Ltd.’s P/E ratio compare with its history?

On this page, ROIV's current P/E is -91.2, compared with a multi-year average around 3.9. A lower P/E versus its own history is a calculated gap versus that average—not a conclusion that the stock is cheap. Pair it with profitability and earnings quality in the table (for example ROE/ROIC) to see whether the multiple moved with earnings.

What is Roivant Sciences Ltd. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $25.02B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Roivant Sciences Ltd.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Roivant Sciences Ltd.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Roivant Sciences Ltd. compare to its competitors in key financial ratios?

The fastest way to compare Roivant Sciences Ltd. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Roivant Sciences Ltd. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Roivant Sciences Ltd.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Roivant Sciences Ltd. is financially strong. Current ratio is about 16.72, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about 0.00, implying less buffer for servicing interest costs. Debt-to-equity is about 0.03, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Roivant Sciences Ltd.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Roivant Sciences Ltd. is sustaining strong returns (for example ROE at -6.12% and ROIC at -27.14%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.